Pharmaceutical composition for preventing and / or treating Parkinson's disease and application thereof

By combining nervonic acid and salvianolic acid A to promote neuronal repair and gut microbiota regulation in Parkinson's disease, this approach addresses the problem that existing drugs cannot stop disease progression and gut microbiota dysbiosis, achieving significant relief of Parkinson's disease symptoms and neuroinflammation.

CN121177274APending Publication Date: 2025-12-23ZHEJIANG UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511364480.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-23
Publication Date
2025-12-23

AI Technical Summary

Technical Problem

Existing levodopa treatments for Parkinson's disease can only improve symptoms but cannot stop disease progression. They also have problems such as short drug half-life, strong drug resistance, and many side effects. Furthermore, gut microbiota dysbiosis may be an early marker of Parkinson's disease, affecting dopamine levels in the brain and accelerating disease progression.

Method used

The combination of nervonic acid and salvianolic acid A promotes the repair of neurons in Parkinson's disease, reduces neuroinflammation, and treats Parkinson's disease by regulating the gut microbiota, using the brain-gut axis as the therapeutic target.

Benefits of technology

It significantly alleviates motor symptoms in a mouse model of Parkinson's disease, promotes the proliferation of neurons and neural stem cells, reduces neuroinflammation, reshapes the distribution of gut microbiota, and improves Parkinson's disease symptoms. Moreover, the composition has high biosafety and low sensitization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121177274A_ABST
    Figure CN121177274A_ABST
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition for preventing and / or treating Parkinson's disease and application of the pharmaceutical composition, and relates to the technical field of biological medicine. The composition comprises nervonic acid, salvianolic acid A and pharmaceutically acceptable auxiliary materials. Experiments prove that the composition can improve intestinal flora, obviously promote alleviation of symptoms of a Parkinson's disease model animal, promote regeneration of dopaminergic neuronal cells and neural stem cells, relieve neuroinflammation, promote repair of damaged nerves, improve dyskinesia of mice caused by Parkinson's disease and improve the Parkinson's disease resistance of the mice. Therefore, the polypeptide has potential application value in treatment of the human Parkinson's disease. According to the invention, the effect of the composition is confirmed from the perspective of improving the change of intestinal flora by utilizing the relationship of the brain-intestinal axis, and a basis is provided for intervening the treatment of Parkinson's disease through the intestinal flora.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a pharmaceutical composition for the prevention and / or treatment of Parkinson's disease and its application. Background Technology

[0002] Parkinson's disease (Parkinson's disease) is the second most prevalent neurodegenerative disease after Alzheimer's, and has become a global health problem. In Parkinson's patients, a large number of dopaminergic neurons die in the ventral pars compacta of the substantia nigra in the midbrain, with some patients losing up to 70% of their neurons. This leads to dopamine deficiency and dysfunction in neural circuits related to movement and the limbic system. Furthermore, persistent neuroinflammation plays a crucial role in the progression of Parkinson's disease, manifested as the activation of immune cells and the release of large amounts of inflammatory factors, exacerbating neuronal damage. Currently, levodopa is the most common drug for treating Parkinson's disease, offering some efficacy throughout the disease's course. However, dopamine replacement therapy cannot repair nerve damage; it can only improve symptoms but not stop disease progression. It also suffers from numerous side effects, including a short half-life, strong drug resistance, behavioral fluctuations in patients, and gastrointestinal reactions. Therefore, the development of novel drugs remains a pressing issue and a hot research topic in the treatment of Parkinson's disease, especially drugs targeting neuroinflammation and neuronal damage.

[0003] The brain-gut axis refers to the bidirectional signal transmission pathway between the brain and the gut. The vagus nerve is the main neural pathway in the brain-gut axis, and the gut can influence brain function through various pathways, including chemical and neural signals. Among these, the gut microbiota is an important regulator of neurodegenerative diseases such as Parkinson's disease, and gut microbiota dysbiosis may be one of the early markers of Parkinson's disease. Gut microbiota imbalance promotes the abnormal folding and aggregation of α-synuclein, which is transmitted to the brain via the vagus nerve, triggering the pathological changes of Parkinson's disease. Simultaneously, the gut microbiota affects intestinal metabolites, indirectly affecting dopamine levels in the brain and accelerating the progression of Parkinson's disease. Therefore, the gut microbiota and the brain-gut axis may be novel targets for the treatment of Parkinson's disease. Summary of the Invention

[0004] To overcome the shortcomings of existing drugs, this invention provides a pharmaceutical composition for the prevention and / or treatment of Parkinson's disease and its application. This invention alleviates Parkinson's disease by promoting neuronal repair and reducing neuroinflammation; simultaneously, it provides adjunctive therapy for Parkinson's disease by regulating the gut microbiota, which has significant value and implications for the further development of drugs utilizing the brain-gut axis to treat neurodegenerative diseases.

[0005] To achieve the above objectives, the present invention adopts the following technical solution:

[0006] The present invention provides a pharmaceutical composition for the prevention and / or treatment of Parkinson's disease and its application thereto, the composition comprising nervonic acid, salvianolic acid A and pharmaceutically acceptable excipients.

[0007] Furthermore, the structural formula of the nervonic acid is shown in formula (I):

[0008]

[0009] Furthermore, the nervonic acid can be derived from sources such as garlic fruit or maple, or obtained using modern biological synthesis techniques.

[0010] Furthermore, the structural formula of the salvianolic acid A is shown in Figure (II):

[0011]

[0012] Furthermore, the salvianolic acid A can be derived from tanshinone or obtained using modern biological synthesis techniques.

[0013] Furthermore, the concentration of nervonic acid in the composition is 1-40 mg / mL, the concentration of salvianolic acid A is 1-20 mg / mL, and the mass ratio of nervonic acid to salvianolic acid A is 1:1 to 10:1, preferably 4:1.

[0014] Furthermore, the pharmaceutically acceptable excipients in the composition include at least one of diluents, binders, disintegrants, lubricants, solvents, solubilizers, cosolvents, emulsifiers, and surfactants.

[0015] Preferably, the preparation method of the composition includes the following steps: adding nervonic acid to corn oil and adding salvianolic acid A to water, heating both mixtures in a water bath at 40-55°C until completely dissolved; adding Tween-80 (Tween-80 volume is 5-15 Vol%) to the salvianolic acid A aqueous solution and stirring until completely dissolved; slowly adding the nervonic acid corn oil solution dropwise while stirring. Finally, using a probe for ultrasonic emulsification, the ultrasonic power is 300-600W, each ultrasonic session lasts 10-20 seconds, with a 5-10 second interval, for a total of 5-20 minutes, and the composition is obtained after ultrasonic dispersion.

[0016] On the other hand, the present invention also provides the use of the described composition in the preparation of a medicament for the prevention and / or treatment of Parkinson's disease.

[0017] Furthermore, the dosage form of the medicine for the prevention and / or treatment of Parkinson's disease is an oral dosage form, such as powder, tablet, capsule, and liquid.

[0018] Furthermore, the drug for the prevention and / or treatment of Parkinson's disease is a drug that utilizes the brain-gut axis to treat neurodegenerative diseases.

[0019] Furthermore, the drugs used for the prevention and / or treatment of Parkinson's disease are drugs that promote nerve repair, neuronal and neural stem cell regeneration, alleviate neuroinflammation, and / or improve gut microbiota.

[0020] The reagents and raw materials used in this invention are all commercially available.

[0021] Compared with the prior art, the beneficial effects of the present invention include:

[0022] 1) The composition provided by the present invention can effectively alleviate the motor symptoms of MPTP-induced Parkinson's disease model mice.

[0023] 2) The composition provided by the present invention can significantly promote the proliferation of neurons, neural stem cells and glial cells in the substantia nigra region of the brain of Parkinson's disease model mice, promote nerve repair and alleviate Parkinson's disease symptoms.

[0024] 3) The composition provided by the present invention can significantly alleviate neuroinflammation in Parkinson's disease model mice, regulate microglia phenotype, thereby accelerating nerve repair and reducing Parkinson's disease symptoms.

[0025] 4) The composition provided by the present invention can target the gut-brain axis, change the distribution of beneficial and harmful bacteria in the gut, thereby reducing intestinal oxidative stress, changing intestinal flora metabolites, relieving neuroinflammation and exerting neuroprotective effects, and alleviating Parkinson's disease symptoms.

[0026] 5) The nervonic acid composition provided by the present invention has extremely high biosafety, does not exhibit toxicity, has good compatibility, and has extremely low sensitization. Attached Figure Description

[0027] Figure 1 The duration, distance, and speed of the spinner when the mouse fell on the spinner in Example 2 are recorded.

[0028] Figure 2 The number of active neurons in H&E staining in Example 3;

[0029] Figure 3 This represents the percentage of the area occupied by Nissl body positive neurons in Example 3;

[0030] Figure 4 This represents the percentage of the area of ​​the tyrosine hydroxylase-positive region in Example 3.

[0031] Figure 5 The image shows the immunofluorescence results of the neuronal cell nucleus (NeuN) and nestin in Example 4.

[0032] Figure 6This is an immunofluorescence result of type I arginase (ARG1) and inducible nitric oxide synthase (iNOS) in Example 4;

[0033] Figure 7 This is an image showing the immunofluorescence results of myelin basic protein (MBP) in Example 4;

[0034] Figure 8 These are the top 20 genera in terms of relative abundance in the gut microbiota in Example 5;

[0035] Figure 9 The results of the linear discriminant analysis (LEfSe) of differentially expressed gut microbiota genera in Example 5 are shown.

[0036] Figure 10 The results of the T-test for the differentially expressed genera of gut microbiota in Example 5 are shown. Detailed Implementation

[0037] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0038] Example 1: Preparation of Compositions at Different Concentrations

[0039] Weigh 80 mg of nervonic acid crystals and add them to 4 mL of corn oil. Add 20 mg of salvianolic acid A crystals to 5.4 mL of water and heat in a 55°C water bath until completely dissolved. Then, add 0.6 mL of Tween-80 to the salvianolic acid A aqueous solution and stir until completely dissolved. While stirring, add the nervonic acid-corn oil solution dropwise. Then, place the mixture in an ultrasonic cell disruptor for sonication in an ice bath at 500 W, with each sonication session lasting 10 seconds followed by a 5-second interval, for a total of 10 minutes. The final composition has a nervonic acid concentration of 8 mg / mL and a salvianolic acid A concentration of 2 mg / mL. Store the prepared composition at -20°C.

[0040] Example 2: The composition promotes the relief of motor symptoms in Parkinson's disease mice

[0041] Select 6-week-old male C 57BL / 6 mice were used to establish a Parkinson's disease model by intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30 mg / kg / day) for 7 consecutive days. Behavioral experiments were then performed for evaluation. A control group, model group, nervonic acid group, salvianolic acid A group, and a combination group were set up, with 6 replicates in each group. The treatment methods for each group are shown in Table 1 below. The volume ratio of each component in the "solvent" listed in the table is: corn oil: water: Tween-80 = 40:54:6. The volume of solvent administered by gavage to each group was the same as that administered by gavage to the combination group.

[0042] Table 1. Treatment methods for different groups in animal experiments

[0043]

[0044] The coordination of mice was measured using an accelerator rotundum, and the mice were trained before the formal experiment. The rotundum was turned on, and its speed was set so that the rotundum's axis accelerated uniformly from 4 rpm to 40 rpm over 5 minutes. The time the mouse remained on the bar, the distance it traveled, and the rotational speed upon falling were measured. Figure 1 As shown, compared with the model group, the mice in the treatment group exercised continuously for a longer time and a greater distance on the rotarod, and their rotation speed upon falling was greater, indicating that the mice's motor coordination was improved. Meanwhile, the combined treatment group showed better therapeutic effects than either component alone, indicating that the combined administration of nervonic acid and salvianolic acid A has a synergistic effect in improving the motor symptoms of Parkinson's disease.

[0045] Example 3: The composition promotes the repair of dopamine neurons in PD mice.

[0046] The experiment was conducted using the animal experimental protocol described in Example 2. Mouse brain tissue from each group was collected, fixed, dehydrated, and embedded in paraffin for sectioning.

[0047] Hematoxylin-eosin staining: After dewaxing, wash the sections and stain with hematoxylin for 5 min. Then, briefly expose the sections to hydrochloric acid solution for 2 s, followed by differentiation with ammonia solution for 15-30 s. Wash the sections, dehydrate them with 95% ethanol, and then stain with eosin solution for 5-8 s. After dehydration and mounting, examine under a microscope and acquire images. Figure 2 As shown, compared with the model group, the neurons in the treatment group mice exhibited better morphology and increased number. Furthermore, the combined treatment group showed better therapeutic effects than either component alone, indicating that the combined administration of nervonic acid and salvianolic acid A has a synergistic neuroprotective effect.

[0048] Nissl staining: After dewaxing the sections, add Nissl body staining solution and stain for 5 minutes. Wash three times with pure water, dehydrate, mount, and then examine under a microscope and acquire images. Nissl bodies in neurons appear as dark blue granules, cell nuclei appear as light blue, and the background is light blue. Figure 3As shown, compared with the model group, the area of ​​Nissl bodies in the treated mice was significantly increased. Furthermore, the combined treatment group showed better therapeutic effects than either component alone, indicating that the combined administration of nervonic acid and salvianolic acid A has a synergistic neuroprotective effect.

[0049] Immunohistochemistry of tyrosine hydroxylase: Sections were blocked with serum at room temperature for 30 min. TH-specific primary antibody and HRP-labeled secondary antibody were added sequentially, followed by DAB staining. Nuclei were counterstained with hematoxylin, and the sections were dehydrated, mounted, and examined under a microscope for image acquisition. Nuclei showed blue expression, while DAB-positive areas showed brownish-yellow expression. Figure 4 As shown, compared with the model group, the area of ​​tyrosine hydroxylase-positive regions in the treatment group mice was significantly increased. Furthermore, the combined treatment group showed better therapeutic effects than either component alone, indicating that the combined administration of nervonic acid and salvianolic acid A has a synergistic neuroprotective effect.

[0050] Example 4: Composition promotes nerve cell repair in PD mice

[0051] Experiments were conducted using the animal experimental protocol described in Example 2. Mouse brain tissue was collected from each group, fixed, dehydrated, and embedded in paraffin for sectioning. Immunofluorescence staining was performed on the tissue sections. The sections were then placed in antigen retrieval buffer for antigen retrieval, followed by blocking with 5% bovine serum albumin for 20 min. Subsequently, the samples were incubated with FITC-labeled secondary antibody for 2 h, and then incubated with 3 mg / mL DAPI solution for nuclear staining. During immunofluorescence staining, primary antibodies against NeuN, Nestin, Arg1, iNOS, and MBP, as well as HRP-labeled secondary antibody, were added for incubation. The samples were examined under a fluorescence microscope, and images were acquired.

[0052] The neuronal nucleus (NeuN) and nestin are markers of neurons and neural stem cells, respectively. NeuN and Nestin staining is shown in the image. Figure 5 As shown, compared with the model group, the treatment group exhibited significantly increased fluorescence signals of NeuN and Nestin, indicating that the composition can promote neuronal repair and neural stem cell proliferation. Furthermore, the therapeutic effect of the composition group was superior to that of any single component, suggesting that the combined application of nervonic acid and salvianolic acid A has a synergistic effect in protecting neurons and promoting neural stem cell proliferation.

[0053] Type I arginine oxidase (ARG1) and inducible nitric oxide synthase (iNOS) are markers of M2 and M1 microglia, respectively. The reduction of neuroinflammation in Parkinson's disease depends on the activation of M2 microglia. ARG1 and iNOS staining results are shown below. Figure 6As shown, compared with the model group, the treatment group exhibited a significant increase in ARG1 fluorescence signal and a significant decrease in iNOS fluorescence signal, indicating that the composition can promote the transformation of M1 microglia to M2 type to alleviate neuroinflammation. Furthermore, the therapeutic effect of the composition group was superior to that of any single component, suggesting that the combined administration of nervonic acid and salvianolic acid A has a synergistic effect in alleviating neuroinflammation.

[0054] Myelin basic protein (MBP) is a marker of oligodendrocytes. MBP staining results are as follows: Figure 7 As shown, compared with the model group, the MBP fluorescence intensity in the treatment group was significantly increased, indicating that the composition can promote the proliferation of oligodendrocytes and thus promote the recovery of damaged nerve fibers. Meanwhile, the therapeutic effect of the composition group was better than that of any single component, indicating that the combined application of nervonic acid and salvianolic acid A has a synergistic effect in repairing nerve fibers.

[0055] Example 5: Effects of Nervonic Acid Composition on Gut Microbiota in Parkinson's Mice

[0056] Fecal samples were collected from the model group and high-dose group in the animal experimental protocol described in Example 2. Next-generation sequencing was performed on the V3-V4 variable region using 16S rDNA to analyze the composition of the fecal intestinal flora. The results were divided into a model group and a treatment group.

[0057] At the genus level, the average composition of bacterial communities is as follows: Figure 8 As shown in the figure, compared with the model group, the abundance of Lactobacillus and Akkermansia in the gut microbiota of mice in the treatment group was increased, while the abundance of Alistipes and Odoribacter was decreased.

[0058] Linear discriminant analysis (LEfSe) was used to assess the significance of differences in specific microbial groups within the gut microbiota. The LDA score is a statistical indicator that quantifies the degree of difference in microbial abundance between groups; a higher absolute score indicates a more significant contribution of that microorganism to the difference between groups. In this example, |LDA| > 2.0 was used as the criterion for screening significant differences. Figure 9 As shown, at the genus level, compared with the model group, the abundance of Akkermansia and Prevotellaceae_NK3B31 in the gut microbiota of mice in the treatment group was increased, while the abundance of Alistipes and Odoribacter was decreased.

[0059] The Student's t-test was used to analyze the statistical differences in microbial abundance between groups. The t-test compares the differences in the means of two groups and calculates the p-value to assess the significance of the difference. In this example, p < 0.05 was used as the screening criterion for significant difference. Figure 10 As shown, compared with the model group, the abundance of Akkermansia and Prevotellaceae_NK3B31 in the gut microbiota of mice in the treatment group was increased, while the abundance of Odoribacter was decreased.

[0060] The above results indicate that the composition can remodel the gut microbiota of Parkinson's mice, showing an increase in the abundance of beneficial bacteria genus Akkermansia and Prevotellaceae_NK3B31. The increase in the abundance of these two genera helps maintain the integrity of the intestinal barrier and the synthesis of short-chain fatty acids, which helps alleviate neuroinflammation in Parkinson's disease. At the same time, it reduces the abundance of Odoribacter, a genus that is upregulated in Parkinson's disease.

[0061] The results above show that the composition provided by this invention can effectively solve problems such as neuronal loss, neuroinflammation and intestinal flora disorder in Parkinson's disease patients, and has potential clinical application prospects.

[0062] In the description of this specification, the references to terms such as "one embodiment / mode," "some embodiments / modes," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment / mode or example is included in at least one embodiment / mode or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment / mode or example. Moreover, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments / modes or examples. Furthermore, without contradiction, those skilled in the art can combine and integrate the different embodiments / modes or examples described in this specification, as well as the features of different embodiments / modes or examples.

[0063] The above description is merely a specific embodiment of the present invention, enabling those skilled in the art to understand or implement the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. It should be noted that those skilled in the art can make several modifications and improvements without departing from the concept of the invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of the present invention should be determined by the appended claims.

Claims

1. A pharmaceutical composition for the prevention and / or treatment of Parkinson's disease, characterized in that, The composition includes nervonic acid, salvianolic acid A, and pharmaceutically acceptable excipients.

2. The composition according to claim 1, characterized in that, The structural formula of the nervonic acid is: The structural formula of salvianolic acid A is:

3. The composition according to claim 1, characterized in that, The composition contains nervonic acid at a concentration of 1-40 mg / mL, salvianolic acid A at a concentration of 1-20 mg / mL, and the mass ratio of nervonic acid to salvianolic acid A is 1:1 to 10:

1.

4. The composition according to claim 1, characterized in that, The pharmaceutically acceptable excipients include at least one of the following: diluents, binders, disintegrants, lubricants, solvents, solubilizers, cosolvents, emulsifiers, and surfactants.

5. The composition according to claim 1, characterized in that, The preparation method of the composition is as follows: add nervonic acid to corn oil, add salvianolic acid A to water, and heat in a water bath at 40-55℃ until completely dissolved; add Tween-80 to the salvianolic acid A aqueous solution, the volume of Tween-80 being 5-15 Vol% of the salvianolic acid A aqueous solution, and stir until completely dissolved; add nervonic acid corn oil solution dropwise while stirring; finally, use a probe for ultrasonic emulsification, with an ultrasonic power of 300-600W, each ultrasonic session lasting 10-20 seconds, with an interval of 5-10 seconds, for a total of 5-20 minutes, and the composition is obtained after ultrasonic dispersion.

6. Use of the composition according to any one of claims 1-5 in the preparation of a medicament for the prevention and / or treatment of Parkinson's disease.

7. Use of the composition according to any one of claims 1-5 in the preparation of a medicament for regulating intestinal flora.

8. The application according to claim 6, characterized in that, The drug is in the form of an oral medication.